A multicentre randomized open‐label phase 2 trial of dexamethasone plus glycyrrhizinate versus dexamethasone in newly diagnosed immune thrombocytopenia

Documenti analoghi

• An open‐label, prospective trial to evaluate the efficacy and safety of ixazomib in combination with cyclophosphamide and dexamethasone in patients with newly diagnosed POEMS syndrome
  di: Haiyan He, et al.
  Pubblicazione: (2024)
• Efficacy and safety of eltrombopag in combination with dexamethasone as first‐line treatment in adult patients with newly diagnosed immune thrombocytopenia
  di: Annaïse J. Jauch, et al.
  Pubblicazione: (2026)
• Reduced dose prednisone plus eltrombopag for the treatment of newly diagnosed adult primary immune thrombocytopenia: A prospective, multicentre, phase 2 clinical trial
  di: Qi Liu, et al.
  Pubblicazione: (2025)
• Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab‐naïve relapsed multiple myeloma
  di: Danai Dima, et al.
  Pubblicazione: (2024)
• Anti‐ CD38 therapy in immune thrombocytopenia ( ITP )
  di: Waleed Ghanima, et al.
  Pubblicazione: (2026)